Category: Neurology
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
How LSD and classic psychedelics are re-entering modern psychiatry
Definium’s CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
2025 in Review: Global biotech and funding trends
Deepali Suri, President of ICON Biotech, discusses Asia’s clinical trial boom, funding shifts, and why neurology and cardiology are surpassing oncology.
-
Rapid Nexus study challenges neuropathy as the point of no return
New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.
-
Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan
EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.
-
Old becomes New: CNS Pharma’s quest to tackle brain cancers
CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.
-
AC Immune’s stock rises with positive Phase II data
Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson’s treatment.
-
Dicot Pharma unlocks sustained ED effect with LIB-01
Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.
-
mRNA technology set to revolutionize snakebite treatment
UK researcher Prof. Vaiyapuri discusses how Covid vaccine technology could soon neutralize deadly snake venom, preventing death and disability for millions.
-
Circio bolsters data for circVec circular RNA expression platform
New data shows enhanced performance in heart and brain tissues, broadening the platform’s therapeutic potential and boosting gene expression by 50%.
-
Cultivating cognitive health and calm in an anxious world
Gardening isn’t just a hobby; it’s science-backed therapy for the brain. Gardenuity CEO talks about how it supports patients & caregivers navigating memory loss.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.